Quest Diagnostics IncorporatedDGXNYSE

Overview Intelligence Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

prnewswire.com

Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results

New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risks SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.

businesswire.com

Digi Power X Graduates to Cboe Canada

TORONTO--(BUSINESS WIRE)---- $DGX #Cboe--Digi Power X Inc. has graduated from the venture markets and is now listed under the symbol DGX on Cboe Canada,.

defenseworld.net

Quest Diagnostics Incorporated (NYSE:DGX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average

zacks.com

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

prnewswire.com

Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer

Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive team SECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and acquisitions (M&A), has joined the company as senior vice president, chief strategy and M&A officer.

prnewswire.com

Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference

SECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Leerink 2026 Global Healthcare Conference in Miami on Wednesday, March 11, 2026, at 8:00 a.m.

zacks.com

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

defenseworld.net

Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock

Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) SVP Patrick Plewman sold 958 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $204.83, for a total transaction of $196,227.14. Following the completion of the sale, the senior vice president directly owned 15,838 shares

defenseworld.net

Compass Wealth Management LLC Makes New Investment in Quest Diagnostics Incorporated $DGX

Compass Wealth Management LLC bought a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,564 shares of the medical research company's stock, valued at approximately $679,000. Other institutional investors also

zacks.com

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

youtube.com

Quest Diagnostics CEO on using blood testing for Alzheimer's diagnosis

Quest Diagnostics CEO Jim Davis says the company's Alzheimer's testing through blood work can help disagnons the disease a lot sooner and get patients into specialist earlier.

gurufocus.com

Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Collaborations Propel Future Outlook

Consolidated Revenues: $2.81 billion, up 7.1% year-over-year.Organic Revenue Growth: 6.4% in the fourth quarter.Diagnostic Information Services Revenue Growth:

seekingalpha.com

Quest Diagnostics Incorporated (DGX) Q4 2025 Earnings Call Transcript

zacks.com

Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up

DGX tops Q4 EPS and revenue estimates as volumes rise, shares jump premarket, and 2026 guidance points to steady growth.

zacks.com

Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com

Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.35 per share. This compares to earnings of $2.23 per share a year ago.

reuters.com

Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand

Quest Diagnostics on Tuesday forecast 2026 profit and revenue above Wall Street estimates after beating expectations for fourth-quarter results on strong demand for its diagnostic tests.

prnewswire.com

Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share

Fourth quarter revenues of $2.81 billion, up 7.1% from 2024 Fourth quarter reported diluted earnings per share ("EPS") of $2.18, up 11.8% from 2024; and adjusted diluted EPS of $2.42, up 8.5% from 2024 Full year revenues of $11.04 billion, up 11.8% from 2024 Full year reported diluted EPS of $8.75, up 13.8% from 2024; and adjusted diluted EPS of $9.85, up 10.3% from 2024 Full year cash from operations of $1.89 billion Full year 2026 revenues expected to be between $11.70 billion and $11.82 billion Full year 2026 reported diluted EPS expected to be between $9.45 and $9.65; and adjusted diluted EPS expected to be between $10.50 and $10.70 SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2025.

prnewswire.com

Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization

SECAUCUS, N.J., Feb. 10, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that the Company's Board of Directors has authorized a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80 per share.

zacks.com

Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings

DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance